Brind.

Genmab Reports Positive Phase 3 Results for Rina-S in Ovarian Cancer

1 report, 1 independent Updated Oct 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Genmab announced positive topline results from the global Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer (PROC). The trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS). In the ITT population, Rina-S demonstrated a 71% reduction in the risk of disease progression or death.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The positive results for Rina-S, an investigational antibody-drug conjugate, advance Genmab's ambition to lead in gynecologic oncology. The company plans to submit the findings for presentation at a future medical meeting and discuss them with regulatory authorities worldwide.

From finanznachrichten.de

Who's involved

  • GenmabDanish healthcare company reporting the positive clinical trial results for Rina-S.
  • FDARegulatory body that reviews Genmab's drug development submissions.
  • AbbViePharmaceutical company maintaining a formal partnership with Genmab for drug development.
  • Johnson & JohnsonMultinational manufacturer from which Genmab receives royalty revenue.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • NasdaqSpeculative

    Nasdaq might see changes in stock price due to investor confidence following the positive clinical results.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped